Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences

Kimberly-Clark

These stocks all pay more than 3% in dividends.

3 High-Yielding Dividend Stocks That Could See Hikes in January

PITTSBURGH , Dec. 23, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023.

Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference

Apple

Albemarle

Disney

Devon Energy

Grayscale Ethereum Mini Trust

It's tough being in the Christmas spirit this year after a dismal 2022 for the stock market. However, there is cause for optimism, as signs of recovery are present this holiday season.

The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year

Biogen

BioNTech SE

Incyte

Inspire Medical Systems Inc

Eli Lilly

Veeva Systems

Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks.

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

The contribution includes donations to four organizations: Direct Relief, World Central Kitchen, WaterAid and World Food Program USA   PITTSBURGH , Dec. 14, 2022 /PRNewswire/ -- Viatris Inc.  (NASDAQ: VTRS), a global healthcare company, today announced it is donating a total of $1 million to aid in supporting access to healthcare, food security and water stewardship in communities around the world, through four organizations: Direct Relief, World Central Kitchen (WCK), WaterAid and World Food Program USA, the U.S. partner of the United Nations World Food Programme.  "As a signatory to the UN Global Compact and supporter of the UN Sustainable Development Goals, we believe companies can play an important role in helping to enable potential solutions to some of society's most pressing challenges," said Michael Goettler , CEO of Viatris.

Viatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship

PITTSBURGH , Dec. 14, 2022 /PRNewswire/ --  Viatris Inc.  (NASDAQ: VTRS), a global healthcare company, today announced that its near-term science-based emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). SBTi is a global body enabling businesses to set ambitious emissions reduction targets in line with the latest climate science.

Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi)

Calliditas Therapeutics AB

Calliditas announces that it has entered into an agreement with Viatris to bring Nefecon®, a specialty therapy focused on downregulating IgA1, to Japanese patients. The agreement, worth up to $100M in upfront and milestone payments, combines Calliditas' specifically formulated drug candidate with Viatris' development, marketing and sales expertise.

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

Oyster Point Pharma Inc

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oyster Point Pharma, Inc. (NasdaqGS: OYST) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Oyster Point will receive $11.00 in cash plus a contingent value right for a potential cash payment of up to $2.00 per share, for each share of Oyster Point that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

Verizon

These stocks have dividend yields exceeding 4%.

Want $3,000 in Dividend Income Next Year? Invest $50,000 in These 2 Stocks

Completes the multi-billion-dollar, cash & stock deal Creates a unique, fully integrated, leading global biosimilars enterprise with eight commercialized products Biocon Biologics will recognize the combined revenue & associated profits from the acquired collaboration biosimilars with immediate effect Viatris to provide commercial and other services for up to 2 years to ensure a seamless transition and continued service to patients and customers BENGALURU, India , Nov. 29, 2022 /PRNewswire/ --  Biocon Biologics Ltd. , a subsidiary of Biocon Ltd.

Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business

Receives a $2 Billion Cash Payment and $1 Billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Biocon Biologics Marks the First in a Series of Expected Initiatives to Reshape and Rebase Viatris, Aimed at Setting it Up for Long-term Growth PITTSBURGH , Nov. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that it has closed its transaction with Biocon Biologics Limited ("Biocon Biologics"), creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader. Viatris and Biocon Biologics have entered a Transition Services Agreement (TSA) pursuant to which Viatris will provide commercialization and certain other transition services for an expected two-year period intended to ensure business continuity for patients, customers and colleagues.

Viatris Completes Biosimilars Transaction with Biocon Biologics

AbbVie

These pharmaceutical companies are profitable and offer above-average dividends.

Better Dividend Stock: AbbVie or Viatris?

PITTSBURGH , Nov. 18, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named the winner in three categories at the 10th annual LMG Life Sciences 2022 Americas Awards, highlighting companies, law firms and legal practitioners behind the most innovative and challenging life science work in the regulatory, corporate, intellectual property and litigation areas. Viatris received the recognition as U.S. In-House Legal Team of the Year for Intellectual Property Litigation after achieving significant victories in several patent litigation matters.

Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences

If you have ever wondered why stocks seem to inexplicably rise hours and even days before big positive news and begin to weaken before big negative news, an insider mole and his minions may be at work.

Viatris Insider Trading Scheme Busted

Fresenius Medical Care

Pfizer

Three underpriced healthcare stocks provide an opportunity.

3 Stocks With Dividends of 3% or More to Buy on the Dip

Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.

Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort

Prosecutors and regulators say Ramkumar Rayapureddy, global chief information officer, tipped a friend about a regulatory drug approval.

Viatris Executive Charged With Insider Trading

PITTSBURGH , Nov. 10, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca's Symbicort® patent, U.S. Patent No.

Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent

Hasbro

Paramount Global

Together, these stocks will ensure you're receiving a dividend each month of the year.

Want to Collect a High Dividend Every Month? Buy These 3 Stocks

Viatris' business is holding up better than expected, despite FX headwinds. A new path to growth clears visibility for investors as the company targets to be the next ophthalmology leader.

Viatris: A Spinoff That Got Even More Interesting

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma, Inc. ("Oyster Point" or the "Company") (NASDAQ: OYST), in connection with the proposed acquisition of the Company by Viatris Inc. (NASDAQ: VTRS) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $11.00 in cash for each share of Oyster Point common stock owned, plus a contingent value right ("CVR") representing the right to receive a potential cash payment of up to $2.00 per share.

SHAREHOLDER ALERT: Weiss Law Investigates Oyster Point Pharma, Inc.

Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.

Why Viatris (VTRS) Is Buying Oyster Point (OYST)

Viatris Inc. (NASDAQ:VTRS ) Q3 2022 Results Conference Call November 7, 2022 8:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Robert Coury - Executive Chairman Michael Goettler - Chief Executive Officer Rajiv Malik - President Dr. Jeff Nau - Oyster Point CEO Sanjeev Narula - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Umer Raffat - Evercore Chris Schott - JPMorgan Gary Nachman - BMO Capital Markets Ash Verma - UBS Jason Gerberry - Bank of America Glenn Santangelo - Jefferies Greg Fraser - Truist Securities Nathan Rich - Goldman Sachs David Amsellem - Piper Sandler Operator Good morning. My name is Gretchen, and I will be your conference operator today.

Viatris Inc. (VTRS) Q3 2022 Earnings Call Transcript

Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.

Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates

Viatris Inc (NASDAQ: VTRS) shares are trading higher by 16.80% to $11.33 Monday morning after the company announced it will acquire Oyster Point Pharma. What Happened?

News for Viatris Stock (VTRS)